Courtesy of Benzinga.
A previous story published on Benzinga.com (subsequently unpublished) referenced a tweet by Adam Feuerstein indicating his opinion that Alkermes’ drug candidate Bydureon would be approved. Bydureon has not been approved. Neither Alkermes’ CEO nor the FDA have made any statement indicating if the drug will be approved.
For more Benzinga, visit Benzinga Professional Service, Value Investor, and Stocks Under $5.